Daihan Pharmaceutical Co.,Ltd. (KOSDAQ:023910)
South Korea · Delayed Price · Currency is KRW 26,200
-250 (-0.95%)
Aug 3, 2026, 3:30 PM KST
Daihan Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 154,056 | 171,990 | 154,056 | 163,170 | 183,600 | 172,200 | |
Market Cap Growth | -18.13% | 11.64% | -5.59% | -11.13% | 6.62% | -12.90% |
Enterprise Value | 55,444 | 85,789 | 80,167 | 60,093 | 96,028 | 117,564 |
Last Close Price | 26200.00 | 29250.00 | 25333.88 | 25919.62 | 27814.69 | 25531.67 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 5.71 | 6.22 | 4.56 | 5.74 | 7.36 | 7.60 |
PS Ratio | 0.73 | 0.82 | 0.75 | 0.83 | 1.00 | 1.00 |
PB Ratio | 0.51 | 0.57 | 0.56 | 0.66 | 0.82 | 0.85 |
P/TBV Ratio | 0.51 | 0.57 | 0.56 | 0.66 | 0.82 | 0.85 |
P/FCF Ratio | 49.31 | 357.17 | 7.76 | 9.28 | 9.01 | 5.99 |
P/OCF Ratio | 5.91 | 6.72 | 4.32 | 4.20 | 6.33 | 4.24 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.26 | 0.41 | 0.39 | 0.31 | 0.52 | 0.69 |
EV/EBITDA Ratio | 1.38 | 2.12 | 1.77 | 1.35 | 2.28 | 2.90 |
EV/EBIT Ratio | 1.86 | 2.75 | 2.11 | 1.68 | 2.91 | 4.04 |
EV/FCF Ratio | 17.75 | 178.16 | 4.04 | 3.42 | 4.71 | 4.09 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0 | 0 | 0 | - | 0.03 | 0.12 |
Debt / EBITDA Ratio | 0.00 | 0.00 | 0.00 | - | 0.15 | 0.58 |
Debt / FCF Ratio | 0.02 | 0.03 | 0.00 | - | 0.32 | 0.82 |
Net Debt / Equity Ratio | -0.33 | -0.30 | -0.28 | -0.42 | -0.40 | -0.36 |
Net Debt / EBITDA Ratio | -2.45 | -2.22 | -1.70 | -2.35 | -2.16 | -1.80 |
Net Debt / FCF Ratio | -31.56 | -185.91 | -3.89 | -5.94 | -4.47 | -2.53 |
Asset Turnover | 0.62 | 0.62 | 0.66 | 0.69 | 0.67 | 0.65 |
Inventory Turnover | 4.57 | 4.75 | 5.36 | 5.38 | 5.46 | 5.22 |
Quick Ratio | 2.80 | 2.84 | 2.58 | 3.28 | 3.04 | 2.72 |
Current Ratio | 3.61 | 3.64 | 3.22 | 3.87 | 3.65 | 3.20 |
Return on Equity (ROE) | 9.31% | 9.59% | 12.89% | 12.01% | 11.66% | 11.79% |
Return on Assets (ROA) | 5.45% | 5.80% | 7.69% | 7.83% | 7.50% | 6.91% |
Return on Invested Capital (ROIC) | 12.11% | 12.70% | 17.74% | 19.93% | 18.62% | 15.86% |
Return on Capital Employed (ROCE) | 9.70% | 10.30% | 13.50% | 14.20% | 14.10% | 12.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 17.51% | 16.07% | 21.91% | 17.42% | 13.59% | 13.16% |
FCF Yield | 2.03% | 0.28% | 12.88% | 10.77% | 11.10% | 16.71% |
Payout Ratio | 19.26% | 18.79% | 12.82% | 13.20% | 8.45% | 9.30% |
Buyback Yield / Dilution | - | - | - | 1.75% | 0.25% | - |